A common classification framework for histone sequence alterations in tumours: an expert consensus proposal
- PMID: 33779999
- DOI: 10.1002/path.5666
A common classification framework for histone sequence alterations in tumours: an expert consensus proposal
Abstract
The description of genetic alterations in tumours is of increasing importance. In human genetics, and in pathology reports, sequence alterations are given using the human genome variation society (HGVS) guidelines for the description of such variants. However, there is less adherence to these guidelines for sequence variations in histone genes. Due to early cleavage of the N-terminal methionine in most histones, the description of histone sequence alterations follows their own nomenclature and differs from the HGVS-compliant numbering by omitting this first amino acid. Next generation sequencing reports, however, follow the HGVS guidelines and as a result, an unambiguous description of sequence variants in histones cannot be provided. The coexistence of these two nomenclatures leads to confusions for pathologists, oncologists, and researchers. This review provides an overview of tumour entities with sequence alterations of the H3-3A gene (HGNC ID = HGNC:4764), highlights the problems associated with the coexistence of these two nomenclatures, and proposes a standard for the reporting of histone sequence variants that allows an unambiguous description of these variants according to HGVS principles. We hope that scientific journals will adopt the new notation, and that both geneticists and pathologists will include it in their reports. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
Keywords: classification; histone; mutation; neoplasm; nomenclature; sequence; tumour.
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
Similar articles
-
Clinical Implementation and Validation of Automated Human Genome Variation Society (HGVS) Nomenclature System for Next-Generation Sequencing-Based Assays for Cancer.J Mol Diagn. 2018 Sep;20(5):628-634. doi: 10.1016/j.jmoldx.2018.05.006. Epub 2018 Jun 21. J Mol Diagn. 2018. PMID: 29936258
-
Sequence Variant Descriptions: HGVS Nomenclature and Mutalyzer.Curr Protoc Hum Genet. 2016 Jul 1;90:7.13.1-7.13.19. doi: 10.1002/cphg.2. Curr Protoc Hum Genet. 2016. PMID: 27367167
-
Describing structural changes by extending HGVS sequence variation nomenclature.Hum Mutat. 2011 May;32(5):507-11. doi: 10.1002/humu.21427. Epub 2011 Mar 15. Hum Mutat. 2011. PMID: 21309030
-
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.J Mol Diagn. 2017 Jan;19(1):4-23. doi: 10.1016/j.jmoldx.2016.10.002. J Mol Diagn. 2017. PMID: 27993330 Free PMC article. Review.
-
The current state of clinical interpretation of sequence variants.Curr Opin Genet Dev. 2017 Feb;42:33-39. doi: 10.1016/j.gde.2017.01.001. Epub 2017 Jan 31. Curr Opin Genet Dev. 2017. PMID: 28157586 Free PMC article. Review.
Cited by
-
H3G34-mutant diffuse hemispheric glioma with osseous metastases: a case report and literature review.CNS Oncol. 2023 Jun 1;12(2):CNS95. doi: 10.2217/cns-2022-0020. Epub 2023 Mar 15. CNS Oncol. 2023. PMID: 36919796 Free PMC article. Review.
-
Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas.Acta Neuropathol Commun. 2022 Mar 31;10(1):42. doi: 10.1186/s40478-022-01335-6. Acta Neuropathol Commun. 2022. PMID: 35361262 Free PMC article.
-
Recurrent Fusion of the Genes for High-mobility Group AT-hook 2 (HMGA2) and Nuclear Receptor Co-repressor 2 (NCOR2) in Osteoclastic Giant Cell-rich Tumors of Bone.Cancer Genomics Proteomics. 2022 Mar-Apr;19(2):163-177. doi: 10.21873/cgp.20312. Cancer Genomics Proteomics. 2022. PMID: 35181586 Free PMC article.
References
-
- den Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat 2016; 37: 564-569.
-
- Deans ZC, Fairley JA, den Dunnen JT, et al. HGVS nomenclature in practice: an example from the United Kingdom National External Quality Assessment Scheme. Hum Mutat 2016; 37: 576-578.
-
- Ogino S, Gulley ML, den Dunnen JT, et al. Standard mutation nomenclature in molecular diagnostics: practical and educational challenges. J Mol Diagn 2007; 9: 1-6.
-
- den Dunnen JT, Paalman MH. Standardizing mutation nomenclature: why bother? Hum Mutat 2003; 22: 181-182.
-
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-424.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources